TGTXTG Therapeutics, Inc.
Is the business good?
The checks split: margins widening and elite returns on assets, but thin cash backing (0.2×).
Mixed fundamental signals. Nine pass/fail tests of year-over-year health from the filings.
Operating profit outpaces operating cash flow, watch accruals and working capital. Conversion is improving vs a year ago.
Profits are tracking sales roughly one-for-one, limited operating leverage either way.
High-quality, exceptional returns on the assets themselves, not leverage. ROE 74% = margin × turnover × leverage.
Unless marked, from derived.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is TGTX?
TG Therapeutics, Inc. earns 14% on the capital it employs against a 9.0% cost of capital, so the business is worth more the bigger it gets.
Return on invested capital · cost of capital 9.0% · 4.5 points above what the capital costs: growth creates value
- Operating margin
- 17%
Operating margin · Biotechnology median −77% · 12 months to Q2 2026
- Cash conversion
- 0.17×
Cash conversion · −0.75× a year ago · the operating profit has not turned into cash yet
- Share count, year on year
- −3.3%
Share count, year on year · bought back, each share owns more of the company
| Year | Operating margin |
|---|---|
| FY2020 | −179996% |
| FY2021 | −5154% |
| FY2022 | −7839% |
| FY2023 | 8.8% |
| FY2024 | 13% |
| FY2025 | 20% |
Details›
- Gross margin12 months to Q2 2026
- 82%
- Operating margin12 months to Q2 2026
- 17%
- Net margin12 months to Q2 2026
- 55%
- Free cash flow margin
- 2.2%
- R&D as % of revenue
- 28%
- Revenue, trailing twelve months
- $800M
- Free cash flow, trailing twelve months
- $17M
- Net income, trailing twelve months
- $441M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- 14%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.